

COMPANY SPOTLIGHT - CSL

CSL is one of the fund's key holdings and is a global leader in human blood plasma-derived therapies.

It provides life-saving medicines to patient populations with a high unmet-medical need. CSL Behring's products are used in over 70 countries to treat immunodeficiencies, bleeding disorders, hereditary angioedema, Alpha 1 antitrypsin deficiency and neurological disorders.

CSL's vaccine business, Seqirus, is the 2nd largest influenza vaccine manufacturer globally. Seqirus produces a broad range of 'flu' vaccines including Fluad, which has been specifically designed for people aged 65 years and over, a particularly vulnerable patient population. Seqirus has committed to donate 10% of its 'flu' vaccine output in the event of a global pandemic. CSL continues to invest in both R&D and capacity expansion launching new products or expanding into new geographies. During 2019, CSL achieved 24 product registrations or new indications for serious diseases and had 34 clinical trials in operation. CSL invested ~US\$1.2billion in capacity expansion in 2019 including manufacturing capacity and new plasma collection centres.

CSL performs well in our ESG framework with notable strengths of 80% board independence, 33% female directors and a detailed modern slavery policy.

KPIs

- R&D spend – US\$832m in 2019, +19% versus 2018.
- Vaccine doses supplied to US market – >50 million doses for 2018/2019 'flu season.



CSL Sub-Goal Alignment:

SDG 3.3: End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases – relevant to Seqirus.

SDG 3.4: Reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being – relevant to CSL Behring.



This Report has been prepared and issued by Melior Investment Management Pty Limited (ACN 629 013 896) (Melior) as the investment manager of the Melior Australian Impact Fund (Fund). The Trust Company (RE Services) Limited (ABN 45 003 278 831) is the responsible entity and issuer of units in the Fund. Melior is a Corporate Authorised Representative (No. 001274055) of Adamantem Capital Pty Limited (ACN 614 857 037, AFSL No. 492717). This information is general information only and is not intended to provide you with financial advice, and has been prepared without taking into account your objectives, financial situation or needs. You should consider the product disclosure statement (PDS) for the Fund, prior to making any investment decisions. The PDS and target market determination (TMD) can be obtained by calling +61 2 9004 6071 or visiting our website www.meliorim.com.au. If you require financial advice that takes into account your personal objectives, financial situation or needs, you should consult your licensed or authorised financial adviser. This information is only as current as the date indicated, and may be superseded by subsequent market events or for other reasons. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. All investments contain risk and may lose value.